Episode Details
Back to Episodes
Merck & Co. Q4 2025 Earnings and Strategic Outlook
Published 6 months ago
Description
Merck’s Q4 2025 results highlight the strategic acquisition of Cidara Therapeutics and the clinical success of Winrevair in PAH. Despite a Gardasil sales decline in Asia and generic headwinds, the firm projects a $70 billion pipeline opportunity driven by oncology and HIV gains.